Primary endpoint reached in phase 2 study in which the mRNA immunotherapy candidate BNT111 is evaluated in combination with the PD-1 checkpoint inhibit...
Triastek Inc. ("Triastek"), a global leader in 3D printing pharmaceuticals, announced that it has entered into a research collaboration and platfor...
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today that the American Medical Assoc...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, provides an overview of advances supporting th...
Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced the completion of $35 Mill...
Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...
Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncology Further data read-outs expected in 2024 in oncology, mental health, ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced that it awarded a total of $1.5 million to 28 organiza...
CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from OurCro...
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media Supports local biopharma manufact...
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, has announced the successful completion of ...
Daiichi Sankyo announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company&r...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital...
© 2025 Biopharma Boardroom. All Rights Reserved.
